Stem Cell Medicine Licenses Exosome Technology for Treating Autism from Ramot at Tel Aviv University
Stem Cell Medicine Ltd. (SCM), a biotechnology company developing new therapies for neurological indications, including mesenchymal stem cells and anti-BMP molecules for the treatment...
FDA approves Roches Tecentriq in combination with Avastin and chemotherapy for the initial treatment of people with a specific type of metastatic lung cancer
Roche announced that the US FDA approved Tecentriq in combination with Avastin, paclitaxel and carboplatin (chemotherapy), for the initial (first-line) treatment of people with...
IQVIAs OCE Technology Platform Selected by Napo Pharmaceuticals to Increase Commercial Efficiency
IQVIA announced that Napo Pharmaceuticals, Inc. (Napo), a wholly-owned subsidiary of Jaguar Health, Inc., has selected Orchestrated Customer Engagement (OCE), IQVIA Technologies’ innovative commercial...
Bluebird bio and Celgene Corporation Present Initial Data from Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy
Bluebird bio, Inc. and Celgene Corporation announced initial data from the ongoing Phase 1 clinical study of bb21217 (CRB-402), an investigational next-generation anti-BCMA CAR...
EMA Accepts Extension Marketing Authorisation Application for Review of Celltrions Remsima SC the subcutaneous version of Remsima
Celltrion, Inc. announced that the EMA has accepted for review of the Extension Marketing Authorisation Application for ‘Remsima SC’, the subcutaneous (SC) version of...
QPS Expands U.S.-Based Phase I Clinical Trial Capabilities to Support the Growing Needs of Its Pharmaceutical, Biotechnology and CRO Partners
QPS, a GLP/GCP-compliant contract research organization (CRO) supporting discovery, preclinical and clinical drug development, announced the expansion of its U.S.-based Phase I clinical trial...
Shire Receives European Approval for TAKHZYRO (lanadelumab) subcutaneous injection for the Preventive Treatment of Hereditary Angioedema
Shire plc the leading global biotechnology company focused on rare diseases, announced that the European Commission (EC) has granted Marketing Authorisation for TAKHZYRO™ (lanadelumab)...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...